From Peptides to Botox: The DOJ Med Spa Enforcement Wave and Florida Prescribers

If you own a med spa, sign protocols as the medical director, or inject as a nurse practitioner or physician assistant in Florida, the federal government just told you where it is looking next. In the span of about five weeks this spring, the FDA issued its first-ever Drug Supply Chain Security Act warning letter to a med spa, and a spa owner in another state pleaded guilty to smuggling counterfeit Botox and admitted to more than a million dollars in client payments. These are not isolated stories. They are the same enforcement wave that has been building on the peptide and compounded drug side, now pointed directly at aesthetic injectables. The agencies running it have already shown they will work backward from a manufacturer's sales records to your treatment notes.

I have spent more than three decades defending healthcare and FDA enforcement cases. The point here is not to scare anyone out of the aesthetics business. It is to explain what the government is actually building, which federal statutes carry real prison exposure, and what prescribers and owners tend to do early, before any charge is filed, that turns a paperwork problem into a criminal case.

The FDA now treats med spas as dispensers under the DSCSA. A unit discrepancy between purchase records and patient charts is enough to open a federal investigation.

Key Takeaways

The FDA now treats med spas as dispensers under the DSCSA, 21 U.S.C. ch. 9 subch. H, which means trading partner and product tracing rules apply to clinics, not just wholesalers.

Counterfeit and smuggled injectable cases are charged under 18 U.S.C. § 545 (smuggling) and 18 U.S.C. § 1343 (wire fraud), with smuggling alone carrying up to 20 years.

The DSCSA gives the FDA a path to enforce without first proving a drug was adulterated or misbranded, which lowers the threshold for action against a clinic.

Florida limits injectable authority to physicians, ARNPs, and PAs under written protocols, Fla. Stat. § 458.347. Gaps in that chain create both licensing and federal exposure.

Florida's volume of med spas and its standing federal districts make it one of the most likely places for the next round of dispenser enforcement.

What Actually Happened This Spring

Two events, weeks apart, define the new posture.

First, on April 1, 2026, the FDA issued a warning letter to a Texas med spa after a multi-day inspection that focused on its handling of Botox. The agency concluded the clinic qualified as a dispenser under the Drug Supply Chain Security Act because its staff were authorized to dispense and administer prescription drugs under a physician's supervision. That is the first DSCSA warning letter ever issued to a dispenser.

The mechanics matter, because they are repeatable against any clinic in the country. FDA investigators compared the number of Botox units the spa bought from the authorized manufacturer against the number of units its own patient records showed it administered. The administered total was far higher than the purchased total. To the FDA, that gap signals product coming in from somewhere other than an authorized trading partner. Investigators also reported finding an unlabeled vial in the trash that lab testing identified as botulinum toxin, with no packaging carrying a required product identifier.

Second, on April 7, 2026, in federal court in Boston, a med spa owner pleaded guilty to importing counterfeit Botox and fillers from China and Brazil and administering thousands of injections while representing herself as a nurse. She was not licensed to inject. Payment records put her client receipts above a million dollars. The counts: four counts of importing merchandise contrary to law, two counts of selling or dispensing a counterfeit drug, and two counts of selling or dispensing a counterfeit device. Sentencing is set for July 1, 2026.

Both events sit on a continuum with the federal counterfeit Botox prosecution out of the Southern District of New York, where a spa operator was charged with wire fraud and smuggling after importing counterfeit product and injecting it without a license, and a client was diagnosed with botulism. Different districts, same template.

What the Government Is Actually Building

The peptide and compounded drug cases taught federal investigators a method, and they are now running it in aesthetics. The method does not start at the clinic. It starts at the manufacturer. AbbVie and Allergan know exactly how many vials each account purchased. When the FDA wants to test a clinic, it does not need a whistleblower or a sick patient. It pulls the manufacturer's sales data, compares it to what the clinic documented administering, and looks at the difference. A clinic that injected more than it legitimately bought has to explain where the extra product came from.

This is why the DSCSA letter is more important than it looks. The statute gives the FDA a basis to pursue a dispenser without first having to prove that any specific drug was adulterated or misbranded. The recordkeeping and trading partner violations are enough to open the door. That lowers the evidentiary threshold and turns a documentation gap into a federal foothold. Once the FDA Office of Criminal Investigations is involved, a civil paperwork problem can become a criminal smuggling or counterfeit drug case.

The pattern to understand: the government can build a med spa case from a manufacturer's purchase records and your own patient charts. It does not need a complaint from a patient to start asking why your numbers do not match.

Anywhere product enters outside the authorized channel creates risk. Gray market sourcing, foreign suppliers, online marketplaces, and borrowed inventory between locations all create the same discrepancy the FDA flagged in Texas. Telehealth prescribing models, standing order protocols that no physician actually reviews, and ARNP or PA injection without a real supervisory relationship add a second layer, because they put the practice of medicine itself in question.

Exposure and Charges: The Statutes That Carry Prison Time

A med spa case is rarely one charge. It is a stack, and the stack is what drives the sentencing exposure. These are the federal statutes that show up most often in this enforcement wave.

18 U.S.C. § 545, smuggling goods or importing merchandise contrary to law. This is the lead charge when product comes from China, Brazil, or another foreign source outside authorized channels. It carries up to 20 years per count.

18 U.S.C. § 1343, wire fraud. Charged when a clinic represents counterfeit or gray market product as genuine, or bills and advertises around that misrepresentation. Up to 20 years per count, and it is the prosecutor's preferred charge because the elements are flexible.

18 U.S.C. § 1347, healthcare fraud. In play whenever an aesthetic or medical indication touches insurance reimbursement, including Botox billed for migraine, hyperhidrosis, or other covered conditions. Up to 10 years per count, more if injury results.

21 U.S.C. §§ 331 and 333, the prohibited acts and penalty provisions of the Food, Drug, and Cosmetic Act. Misbranding and the sale of unapproved or counterfeit drugs live here. A knowing or intent-to-defraud violation becomes a felony.

18 U.S.C. § 2320, trafficking in counterfeit goods, including counterfeit drugs. Penalties climb sharply when the counterfeit product creates a risk of serious bodily injury, which an injectable neurotoxin plainly can.

21 U.S.C. § 360eee and the related DSCSA provisions, the trading partner and product tracing rules now being applied to dispensers. Violations here are often the entry point, not the headline count.

Stack two or three of these and add a loss amount in the hundreds of thousands, and the advisory guideline range moves into multiple years quickly. Restitution rides alongside it. In the Boston plea, prosecutors recommended restitution above one million dollars, tied to the client payments the clinic took in.

The Mistakes That Turn an Inquiry Into an Indictment

Most of the damage in these cases happens before anyone is charged, and it is usually self-inflicted. The recurring errors are predictable.

Talking to FDA or OCI investigators without counsel. Agents who show up at a clinic are not there to clear you. Statements at the counter, in the back room, or by text get quoted in charging documents. You are allowed to be polite, take a card, and say your lawyer will follow up.

Answering a Form FDA 483 with promises instead of proof. In the Texas matter, the FDA escalated to a warning letter specifically because the clinic's response described future intentions without documented policies, procedures, and evidence of actual correction. A 483 response is a legal document. Treat it like one.

Handing over purchase records, patient charts, and inventory logs without a strategy or a litigation hold. Once the manufacturer data and your own records are side by side, the discrepancy speaks for itself. How and when those records are produced matters.

Assuming a warning letter or a civil inspection is the end of it. The same facts that support a DSCSA letter can support a criminal referral. The civil track and the criminal track run on parallel rails, and OCI is a criminal agency.

Waiting for an indictment to hire a lawyer. By the time charges are filed, the sourcing question is usually answered and the leverage is gone. The window to shape the outcome is open before, not after.

The Defense Approach for a Florida Prescriber or Owner

A med spa case is winnable, but the work that wins it is early and quiet. The first goal in a federal investigation is to control what the government learns and when. That means getting counsel involved before the next FDA contact, before the 483 response goes out, and before any voluntary production.

The factual core of most aesthetics cases is sourcing and authority. On sourcing, the defense examines whether the product was in fact counterfeit or simply purchased through a channel the FDA disfavors, whether the unit discrepancy has an innocent explanation such as wastage, overfill, or recordkeeping lag, and whether the government can actually trace a specific counterfeit vial to a specific patient. On authority, the defense looks at whether a genuine supervisory relationship existed, whether protocols were real and followed, and whether the owner, the medical director, and the injector each had a defensible understanding of their role.

That last point is where the criminal statutes have teeth and where the defense has room. Smuggling, wire fraud, and counterfeit trafficking are intent crimes. The government has to prove the person knew. A medical director who signed protocols but never saw the invoices, an injector who trusted the owner's sourcing, and an owner who bought from a vendor that appeared legitimate are not in the same position as someone who knowingly imported fakes at a tenth of the genuine price. Separating knowledge from negligence is the heart of the case, and it drives the rest.

Where the facts are clean and the discrepancy is explainable, the posture is to resist and keep the matter civil. Where exposure is real, early and well-counseled cooperation, with a clear account of who knew what, can be the difference between a target and a witness. Those are not decisions to make alone at the counter while an agent waits.

"Smuggling, wire fraud, and counterfeit trafficking are intent crimes. The government has to prove the person knew. Separating knowledge from negligence is the heart of the case."— Aaron M. Cohen, AMC Defense Law

Why This Is Heading for Florida, and Why Timing Matters

Florida has one of the densest med spa markets in the country and active United States Attorney's Offices in the Middle, Southern, and Northern Districts. The state's rules on who may inject are specific: physicians, ARNPs, and PAs may administer Botox and fillers, but only under written protocols and physician supervision, and registered nurses and aestheticians may not prescribe at all. See Fla. Stat. § 458.347 on physician assistant delegation. When the supervisory chain is a name on paper rather than a real relationship, the same facts that create a state licensing problem feed a federal case about who was actually authorized to dispense.

The DSCSA method does not care which state you are in, and the FDA has signaled this letter is a template, not a one-off. Florida's volume makes it a natural next stop. The time-sensitive reality is simple. Charging decisions are still fluid early in an investigation. A clinic that gets ahead of an inspection, fixes its trading partner documentation, and has counsel ready before the next FDA contact is in a different position than one that waits for a letter and then a subpoena. That window is open now and closes as the file builds.

Common Questions

Facing an FDA Inspection or a Federal Inquiry in Florida?

AMC Defense Law represents med spa owners, medical directors, nurse practitioners, physician assistants, and physicians in FDA, DOJ, and OIG investigations and prosecutions, in Florida and nationwide. If your clinic has received a Form FDA 483, a warning letter, a subpoena, or a target letter, the most valuable work happens before charges are filed. To arrange a confidential consultation, contact AMC Defense Law.

A clinic that gets ahead of an FDA inspection and has counsel in place before the next contact is in a fundamentally different position than one that waits for a subpoena.

If you or your practice has received an FDA 483, a warning letter, a subpoena, or a target letter, or if federal investigators have appeared at your clinic, call Aaron M. Cohen, 24 hours a day to get help.